IFITM1 and prostate adenocarcinoma: In addition, we performed the ROC analysis to evaluate the diagnostic value of IFITM1 in PRAD patients, and the results showed that IFITM1 could differentiate PRAD samples from the normal samples (Supplementary Figure S5, AUC = 0.750).